Androgen Suppression Therapy News and Research

RSS

African-American men treated with ADT for prostate cancer suffer from high mortality rates

In a retrospective study analyzing patients' medical records, researchers at Brigham and Women's Hospital found that patients' race significantly affected their longevity by increasing the likelihood of death after receiving androgen deprivation therapy (ADT).

5 Aug 2016

TAS therapy prior to radiation therapy yields favorable outcomes in PCa patients

A shorter course of androgen suppression therapy prior to radiation therapy, when compared to a longer course of androgen suppression therapy, yields favorable outcomes and fewer adverse effects for intermediate-risk prostate cancer patients, according to research presented today at the American Society for Radiation Oncology's (ASTRO) 55th Annual Meeting.

24 Sep 2013

Intermittent androgen suppression therapy for prostate cancer

Androgen suppression - the inhibition of testosterone and other male hormones - is a routine therapy for prostate cancer. Unfortunately, it can dramatically reduce the quality of patients' sex lives and, more importantly, lead to cancer recurrence in a more deadly androgen-independent form.

28 Mar 2012

Aurora kinase inhibitor may treat neuroendocrine prostate cancer

An international team of researchers led by clinicians at Weill Cornell Medical College have discovered a genetic Achilles' heel in an aggressive type of prostate cancer -- a vulnerability they say can be attacked by a targeted drug that is already in clinical trials to treat other types of cancers.

17 Nov 2011

Decrease in physician reimbursement leads to decline in AST usage for prostate cancer

The use of androgen suppression therapy (AST) in prostate cancer for low-risk cases declined following a decrease in physician reimbursement, according to a study published online TK in The Journal of the National Cancer Institute. However, the indicated use of AST for metastatic disease in the palliative setting did not decline in the same period.

4 Dec 2010

Author evaluates potential benefits of IAD for treating prostate cancer

'Potential Benefits of Intermittent Androgen Suppression Therapy in the Treatment of Prostate Cancer: A Systematic Review of the Literature' is the title of an article by P-A. Abrahamsson in the January issue of European Urology, the official journal of the European Association of Urology. The author evaluates available evidence regarding the efficacy and tolerability of intermittent androgen deprivation (IAD) and assess its value in the treatment of prostate cancer (PCa).

5 Jan 2010

AUA counters mainstream recommendations with new best practice statement on PSA testing

The American Urological Association (AUA) today issued new clinical guidance - which directly contrasts recent recommendations issued by other major groups - about prostate cancer screening, asserting that the prostate-specific antigen (PSA) test should be offered to well-informed, men aged 40 years or older who have a life expectancy of at least 10 years.

27 Apr 2009

Why hormone therapy for prostate cancer fails

Some of the drugs given to many men during their fight against prostate cancer can actually spur some cancer cells to grow, researchers have found. The findings were published online this week in a pair of papers in the Proceedings of the National Academy of Sciences.

21 Aug 2008

Additional biopsy-scoring data may help determine prostate cancer prognosis

Men with certain scores and patterns based on prostate cancer biopsy were found to be at higher risk of PSA-failure, suggesting that this measurement could help predict the risk of prostate cancer recurrence, according to preliminary research published in the October 3 issue of JAMA.

3 Oct 2007

Rate of increase in PSA value predicts risk of death following radiation therapy

Men who have a higher rate of increase in their PSA value in the year prior to their prostate cancer diagnosis have a significantly higher risk of death following radiation therapy, according to a study in the July 27 issue of JAMA: The Journal of the American Medical Association.

26 Jul 2005

Combination therapies improve prostate cancer survival rates

The addition of six months of androgen suppression therapy (AST) to radiation therapy improves survival of patients with clinically localized prostate cancer, according to a study in the current issue of the Journal of the American Medical Association.

18 Aug 2004